

## UPDATED ALOXI AGREEMENT FOR OA MEMBERS

### Additional Rebate and Discount Opportunities



The new contract period for Aloxi will run from **October 1, 2006 to September 30, 2007**. The contract terms (discount tiers and rebates) for the current contract period will remain the same as in the last contract period (October 1, 2005 – September 30, 2006).

Market Share	Discount
<20%	0%
20-49.9%	6%
>50%	12%

- > Market Share will be measured semi-annually for discounts.
- > **5% Rebate opportunity** available for an annual market share of >70%. All rebates will be paid out annually (end of November, 2007).

### Additional Opportunities for New Contract Period (October 1, 2006 to September 30, 2007)

If your practice achieves  $\geq 50\%$  Market Share for the new annual contract period, you will be eligible for additional rebates as follows: **3% Additional Rebate** for all purchases in a given quarter in which your Market Share is  $\geq$  for that particular quarter. While this will be measured quarterly, all rebates will be paid out **annually (end November, 2007)**.

### Loyalty Discount

Any practice that achieves  $\geq 70\%$  market share for the new annual contract period will also receive an **additional 2% discount** starting Q4, 2007 (November 1) through Q3, 2009.

Please contact Oncology Associates at **888-732-7352** with any questions.

## ELOXATIN ADDED TO SANOFI AVENTIS AGREEMENT

Effective January 1, 2007, Eloxatin (oxaliplatin injection) is available to OA Members as part of our agreement with Sanofi Aventis. OA members in good standing will receive a **0.50% discount** on all purchases of Eloxatin. The product is available in **50 mg and 100 mg vials**. The agreement will continue until December 31, 2008.



Eloxatin, used in combination with infusional 5-FU/LV is indicated for:

- > Adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. The indication is based on an improvement in disease-free survival, with no demonstrated benefit in overall survival after a median follow-up of four years.
- > Treatment of advanced carcinoma of the colon or rectum.

OA Members will still continue to receive valuable discounts on purchases of **Taxotere (10.00%)** and **Anzemet (1.00%)**. Please contact Oncology Associates at 888-732-7352 with questions regarding the Sanofi Aventis agreement.

Product	NDC#	Size	Discount
Eloxatin (oxaliplatin injection)	00024-0590-10	50 mg	0.50%
Eloxatin (oxaliplatin injection)	00024-0591-20	100 mg	0.50%
Taxotere (docetaxel)	00075-8001-20	20 mg	10.00%
Taxotere (docetaxel)	00075-8001-80	80 mg	10.00%

## ONDANSETRON NOW AVAILABLE FROM BEDFORD LABORATORIES

Ondansetron Injection USP (AP rated to Zofran®) is now available to OA Members as part of our agreement with Bedford Laboratories. The product is available in the following presentations: 4 mg/2 mL SD vial and 40 mg/20 mL MD vial. Ondansetron Injection USP is Latex free and preservative free (SD vial only). The product is available through FloridaInfusion. Please contact your representative to place an order.

